Syndax Pharmaceuticals, Inc. Financing Cash Flow
Syndax Pharmaceuticals, Inc. (SNDX) reported Financing Cash Flow of $260.69 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-04.
Financial Statements › Cash Flow › Financing Activities
us-gaap:NetCashProvidedByUsedInFinancingActivities · last filed 2026-08-04
- Syndax Pharmaceuticals, Inc. net cash provided by (used in) financing activities for the quarter ending 2026-06-30 was $252.77M, a 45774.77% increase year-over-year.
- Syndax Pharmaceuticals, Inc. net cash provided by (used in) financing activities for the quarter ending 2026-03-31 was $7.92M, a 751.40% increase year-over-year.
- Syndax Pharmaceuticals, Inc. net cash provided by (used in) financing activities for the quarter ending 2025-12-31 was $5.92M, a 98.30% decline year-over-year.
- Syndax Pharmaceuticals, Inc. net cash provided by (used in) financing activities for the quarter ending 2025-09-30 was $6.28M, a 102.65% increase year-over-year.
- Syndax Pharmaceuticals, Inc. net cash provided by (used in) financing activities for fiscal 2025 was $13.68M, a 96.13% decline from fiscal 2024.
- Syndax Pharmaceuticals, Inc. net cash provided by (used in) financing activities for fiscal 2024 was $353.37M, a 33.78% increase from fiscal 2023.
- Syndax Pharmaceuticals, Inc. net cash provided by (used in) financing activities for fiscal 2023 was $264.13M, a 53.34% increase from fiscal 2022.
- Syndax Pharmaceuticals, Inc. net cash provided by (used in) financing activities for fiscal 2022 was $172.25M, a 45.41% increase from fiscal 2021.
| Period end | Net Cash Provided by (Used in) Financing Activities 3 month | Net Cash Provided by (Used in) Financing Activities 6 month | Net Cash Provided by (Used in) Financing Activities 9 month | Net Cash Provided by (Used in) Financing Activities 12 month |
|---|---|---|---|---|
| 2026-06-30 | $252.77M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-04 | $260.69M 10-Q · filed 2026-08-04 | $266.61M derived: sum of 3 quarters · filed 2026-08-04 | $272.88M derived: sum of 4 quarters · filed 2026-08-04 |
| 2026-03-31 | $7.92M 10-Q · filed 2026-04-30 | $13.84M derived: sum of 2 quarters · filed 2026-04-30 | $20.11M derived: sum of 3 quarters · filed 2026-04-30 | $20.66M derived: sum of 4 quarters · filed 2026-08-04 |
| 2025-12-31 | $5.92M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $12.20M derived: sum of 2 quarters · filed 2026-02-26 | $12.75M derived: sum of 3 quarters · filed 2026-08-04 | $13.68M 10-K · filed 2026-02-26 |
| 2025-09-30 | $6.28M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-03 | $6.83M derived: sum of 2 quarters · filed 2026-08-04 | $7.76M 10-Q · filed 2025-11-03 | $355.18M derived: sum of 4 quarters · filed 2026-08-04 |
| 2025-06-30 | $551.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-04 | $1.48M 10-Q · filed 2026-08-04 | $348.91M derived: sum of 3 quarters · filed 2026-08-04 | $352.00M derived: sum of 4 quarters · filed 2026-08-04 |
| 2025-03-31 | $930.00K 10-Q · filed 2026-04-30 | $348.36M derived: sum of 2 quarters · filed 2026-04-30 | $351.45M derived: sum of 3 quarters · filed 2026-04-30 | $352.13M derived: sum of 4 quarters · filed 2026-04-30 |
| 2024-12-31 | $347.43M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $350.52M derived: sum of 2 quarters · filed 2026-02-26 | $351.20M derived: sum of 3 quarters · filed 2026-02-26 | $353.37M 10-K · filed 2026-02-26 |
| 2024-09-30 | $3.10M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-03 | $3.77M derived: sum of 2 quarters · filed 2025-11-03 | $5.94M 10-Q · filed 2025-11-03 | $264.43M derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-06-30 | $676.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-04 | $2.84M 10-Q · filed 2025-08-04 | $261.33M derived: sum of 3 quarters · filed 2026-02-26 | $263.18M derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-03-31 | $2.17M 10-Q · filed 2025-05-05 | $260.65M derived: sum of 2 quarters · filed 2026-02-26 | $262.50M derived: sum of 3 quarters · filed 2026-02-26 | $263.83M derived: sum of 4 quarters · filed 2026-02-26 |
| 2023-12-31 | $258.48M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $260.33M derived: sum of 2 quarters · filed 2026-02-26 | $261.66M derived: sum of 3 quarters · filed 2026-02-26 | $264.13M 10-K · filed 2026-02-26 |
| 2023-09-30 | $1.85M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-05 | $3.17M derived: sum of 2 quarters · filed 2024-11-05 | $5.65M 10-Q · filed 2024-11-05 | $169.15M derived: sum of 4 quarters · filed 2025-03-03 |
| 2023-06-30 | $1.32M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-01 | $3.80M 10-Q · filed 2024-08-01 | $167.30M derived: sum of 3 quarters · filed 2025-03-03 | $153.78M derived: sum of 4 quarters · filed 2025-03-03 |
| 2023-03-31 | $2.47M 10-Q · filed 2024-05-08 | $165.98M derived: sum of 2 quarters · filed 2025-03-03 | $152.45M derived: sum of 3 quarters · filed 2025-03-03 | $174.17M derived: sum of 4 quarters · filed 2025-03-03 |
| 2022-12-31 | $163.50M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-03 | $149.98M derived: sum of 2 quarters · filed 2025-03-03 | $171.70M derived: sum of 3 quarters · filed 2025-03-03 | $172.25M 10-K · filed 2025-03-03 |
| 2022-09-30 | -$13.53M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-02 | $8.20M derived: sum of 2 quarters · filed 2023-11-02 | $8.75M 10-Q · filed 2023-11-02 | $118.53M derived: sum of 4 quarters · filed 2024-02-27 |
| 2022-06-30 | $21.72M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-03 | $22.28M 10-Q · filed 2023-08-03 | $132.06M derived: sum of 3 quarters · filed 2024-02-27 | $133.76M derived: sum of 4 quarters · filed 2024-02-27 |
| 2022-03-31 | $557.00K 10-Q · filed 2023-05-08 | $110.34M derived: sum of 2 quarters · filed 2024-02-27 | $112.04M derived: sum of 3 quarters · filed 2024-02-27 | $118.06M derived: sum of 4 quarters · filed 2024-02-27 |
| 2021-12-31 | $109.78M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-27 | $111.48M derived: sum of 2 quarters · filed 2024-02-27 | $117.50M derived: sum of 3 quarters · filed 2024-02-27 | $118.46M 10-K · filed 2024-02-27 |
| 2021-09-30 | $1.71M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-03 | $7.72M derived: sum of 2 quarters · filed 2022-11-03 | $8.69M 10-Q · filed 2022-11-03 | $147.34M derived: sum of 4 quarters · filed 2023-02-28 |
| 2021-06-30 | $6.02M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-08 | $6.98M 10-Q · filed 2022-08-08 | $145.64M derived: sum of 3 quarters · filed 2023-02-28 | $147.41M derived: sum of 4 quarters · filed 2023-02-28 |
| 2021-03-31 | $960.00K 10-Q · filed 2022-05-09 | $139.62M derived: sum of 2 quarters · filed 2023-02-28 | $141.38M derived: sum of 3 quarters · filed 2023-02-28 | $250.39M derived: sum of 4 quarters · filed 2023-02-28 |
| 2020-12-31 | $138.66M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-28 | $140.43M derived: sum of 2 quarters · filed 2023-02-28 | $249.43M derived: sum of 3 quarters · filed 2023-02-28 | $304.42M 10-K · filed 2023-02-28 |
| 2020-09-30 | $1.77M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-15 | $110.77M derived: sum of 2 quarters · filed 2021-11-15 | $165.77M 10-Q · filed 2021-11-15 | $165.82M derived: sum of 4 quarters · filed 2022-03-01 |
| 2020-06-30 | $109.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-09 | $164.00M 10-Q · filed 2021-08-09 | $164.06M derived: sum of 3 quarters · filed 2022-03-01 | $164.14M derived: sum of 4 quarters · filed 2022-03-01 |
| 2020-03-31 | $55.00M 10-Q · filed 2021-05-11 | $55.06M derived: sum of 2 quarters · filed 2022-03-01 | $55.14M derived: sum of 3 quarters · filed 2022-03-01 | $55.14M derived: sum of 4 quarters · filed 2022-03-01 |
| 2019-12-31 | $58.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-01 | $138.00K derived: sum of 2 quarters · filed 2022-03-01 | $144.00K derived: sum of 3 quarters · filed 2022-03-01 | $28.57M 10-K · filed 2022-03-01 |
| 2019-09-30 | $80.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-05 | $86.00K derived: sum of 2 quarters · filed 2020-11-05 | $28.51M 10-Q · filed 2020-11-05 | $34.66M derived: sum of 4 quarters · filed 2021-03-12 |
| 2019-06-30 | $6.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-06 | $28.43M 10-Q · filed 2020-08-06 | $34.58M derived: sum of 3 quarters · filed 2021-03-12 | $44.04M derived: sum of 4 quarters · filed 2021-03-12 |
| 2019-03-31 | $28.43M 10-Q · filed 2020-05-07 | $34.57M derived: sum of 2 quarters · filed 2021-03-12 | $44.03M derived: sum of 3 quarters · filed 2021-03-12 | $44.12M derived: sum of 4 quarters · filed 2021-03-12 |
| 2018-12-31 | $6.14M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-12 | $15.61M derived: sum of 2 quarters · filed 2021-03-12 | $15.70M derived: sum of 3 quarters · filed 2021-03-12 | $15.73M 10-K · filed 2021-03-12 |
| 2018-09-30 | $9.46M derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-07 | $9.55M derived: sum of 2 quarters · filed 2019-11-07 | $9.58M 10-Q · filed 2019-11-07 | $35.20M derived: sum of 4 quarters · filed 2020-03-05 |
| 2018-06-30 | $89.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-07 | $122.00K 10-Q · filed 2019-08-07 | $25.74M derived: sum of 3 quarters · filed 2020-03-05 | $26.74M derived: sum of 4 quarters · filed 2020-03-05 |
| 2018-03-31 | $33.00K 10-Q · filed 2019-05-08 | $25.65M derived: sum of 2 quarters · filed 2020-03-05 | $26.65M derived: sum of 3 quarters · filed 2020-03-05 | |
| 2017-12-31 | $25.61M derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-05 | $26.62M derived: sum of 2 quarters · filed 2020-03-05 | $75.72M 10-K · filed 2020-03-05 | |
| 2017-09-30 | $1.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-05 | $50.11M 10-Q · filed 2018-11-05 | ||
| 2017-06-30 | $49.10M 10-Q · filed 2018-08-08 | |||
| 2016-12-31 | $54.20M 10-K · filed 2019-03-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Rapport Therapeutics, Inc. (RAPP) | United States | $1.623B | -14.56 |
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |
| Xeris Biopharma Holdings, Inc. (XERS) | United States | $1.632B | -80.10 |
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| ANAPTYSBIO, INC (ANAB) | United States | $1.546B | -60.20 |
| Eton Pharmaceuticals, Inc. (ETON) | United States | $1.701B | 80.74 |
| Innoviva, Inc. (INVA) | United States | $1.493B | 4.62 |
| ArriVent BioPharma, Inc. (AVBP) | United States | $1.485B | -10.25 |
| Ultragenyx Pharmaceutical Inc. (RARE) | United States | $1.456B | -5.62 |
| OMEROS CORP (OMER) | United States | $1.456B | 5.50 |